Redeye provides a research update following the recently published Q4 report from Lipum. While the company reported higher-than-expected expenses due to drug substance production ahead of phase II trials and merger-related costs, this was partly offset by a positive change in working capital. Importantly, Lipum’s merger with majority shareholder Flerie invest is progressing according to plan with expected completion around the end of Q1 2026.
LÄS MER
